PI3Kα E542K, E545K mutant selective inhibitor (OnKure Therapeutics)

N/A

Report date: 2025/03/26 11:40:35
NME

Base Information

Drug NamePI3Kα E542K, E545K mutant selective inhibitor (OnKure Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionPhosphoinositide 3-kinase alpha E542K inhibitorsPhosphoinositide 3-kinase alpha E545K inhibitors
TargetsPhosphatidylinositol 3 kinase alphaPhosphoinositide 3-kinase alpha E542KPhosphoinositide 3-kinase alpha E545K
Therapy Area/IndicationsSolid tumoursBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOnkure Inc
China Registration ClassN/A

Develop Information

Active CompaniesOnkure Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A